|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Departments of Pathology, and Clinical
Pathology, College of Medicine, The Catholic University of Korea,
Seoul, Korea; and Department of Pathology and Cancer Research Center,
Seoul National University, College of Medicine, Seoul, Korea.
Caspase 10 (Mch4/FLICE2) is a caspase homologous to caspase 8. A
recent report described that inherited CASP10 gene
mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome (ALPS). In this study, to
explore the possibility that mutation of this gene might be involved in
the development of non-Hodgkin lymphoma (NHL), we have analyzed the
entire coding region and all splice sites of the CASP10
gene for the detection of somatic mutations in 117 human NHLs.
Overall, 17 NHLs (14.5%) were found to have CASP10 mutations, which were identified in the coding regions of the prodomain (n = 3), the p17 large protease subunit (n = 11), and the
p12 small protease subunit (n = 3). We expressed the tumor-derived caspase 10 mutants in 293 cells and found that apoptosis was
suppressed. These data suggest that the inactivating mutations of the
CASP10 gene might lead to the loss of its apoptotic
function and contribute to the pathogenesis of some human NHLs.
(Blood. 2002;99:4094-4099) Apoptosis is a fundamental biochemical cell death
pathway essential for normal tissue homeostasis, cellular
differentiation, and development.1,2 Dysregulation of
apoptosis may be directly involved in several human diseases, including
degenerative and autoimmune diseases, neoplasia, and acquired
immunodeficiency syndrome.1,2 The death signals
originating from death receptors, such as tumor necrosis factor (TNF)
receptors, Fas, and TNF-related apoptosis-inducing ligand (TRAIL)
receptors, are transduced through the recruitment of procaspase 8 and
10 to the death-induced signaling complex (DISC) by the adaptor
molecule Fas-associated death domain protein (FADD).1 The
local aggregation of the procaspases 8 and 10 is sufficient to allow
autoprocessing or transprocessing to produce active caspases 8 and
10, which can subsequently activate downstream executioners, such
as caspases 3 and 7.3,4 The death receptors are widely
expressed in normal and neoplastic cells,1,5 but the
expression of these proteins does not necessarily predict
susceptibility to killing.6 This can reflect the presence of inhibiting mechanisms of death receptor-mediated apoptosis. The death receptor-mediated apoptosis can be blocked by several mechanisms, including the mutation of the primary structure of death receptors and their ligand.7-10
The consequences of naturally occurring mutants of Fas/Fas ligand
(FasL) have been well demonstrated in both mice and humans. Both
Fas gene-deficient mice (lpr) and
FasL gene-deficient mice (gld) have an
abnormality of mature T-cell deletion in the peripheral tissues,
resulting in lymphadenopathy and systemic autoimmune disease.11 Autoimmune lymphoproliferative syndrome
(ALPS), the human counterpart of lpr and gld
mice, is characterized by an increase in double-negative T cells
and profound lymphadenopathy.4,12,13 Most of the
ALPS patients (ALPS type Ia) have inherited mutations of the
Fas gene.12 In ALPS type Ib, systemic lupus
erythematosus and lymphadenopathy are associated with germ line
mutation of the FasL gene.13 ALPS type II is
manifested by a related clinical phenotype and apoptosis defects in the
absence of either Fas or FasL mutations,
indicating that other modifying factors besides Fas or
FasL mutations affect cell death signaling pathways in these
patients.4,14,15
Recently, Wang and coworkers traced along the Fas-signaling pathway of
2 ALPS type II families.4 They found 2 germ line mutations
of the CASP10 gene, but not of other death-related genes such as Fas, FasL, TRAILR1, TRAILR2, CASP8, or
FADD.4 These caspase 10 mutants had
significantly reduced enzymatic and autoprocessing activities,
and when transfected into mammalian cells, these mutants had a reduced
ability to induce apoptosis, indicating that caspase 10 is defective in
patients with ALPS type II.4
Unlike the embryonic lethality of FADD and caspase 8 deficiencies
reported in knock-out mice,11,16 the CASP10
mutations in ALPS patients exert consequences limited to the control of cell death in the immune system.4 Because the
CASP10 gene mutation results in abnormal lymphocyte
proliferation as in ALPS,4 it is possible that this gene
mutation may be involved in the development of non-Hodgkin lymphoma
(NHL). In addition, the previous loss of heterozygosity (LOH) studies
have suggested that loss of one or more putative tumor suppressor genes
at chromosome 2q33-34, where the CASP10 gene
resides,17 may be involved in the development of
NHL.18 In the present study, we analyzed a series of
117 NHLs for the detection of somatic mutations of the
CASP10 gene, which might lead to a longer survival of
affected tumor cells and contribute to the tumorigenesis of NHL.
Tissue samples and microdissection
Malignant cells and normal cells were selectively procured from
hematoxylin and eosin-stained slides using a 30G1/2 hypodermic needle
(Becton Dickinson, Franklin Lakes, NJ) affixed to a micromanipulator, as described previously.20
Single-strand conformation polymorphism analysis
Because a biallelic polymorphism at nucleotide position 1337 A/G (exon 9) has been found by previous studies4 and additional biallelic polymorphism at nucleotide position 177 A/G (exon 2) has been detected in the present study, SSCP analysis at these polymorphic sites was used for the detection of LOH as well as for the detection of mutations. The PCR and SSCP conditions of LOH study were the same as the conditions described above. Complete or nearly complete absence of one allele in tumor DNA of informative cases, as defined by direct visualization, was considered as LOH. Site-directed mutagenesis Site-directed mutagenesis was performed using a Quick Change Site-Directed Mutagensis kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions. To change a base, a plasmid that contained the CASP10 gene in pcDNA3.1-Myc (Invitrogen, Carlsbad, CA) was used as a template. The sequences of the mutagenized plasmids were confirmed.Coimmunoprecipitations and immunoblotting assay Human embryonic kidney 293 cells were cultured at 37°C in 5% CO2 in Dulbecco modified Eagle medium with 10% heat-inactivated fetal bovine serum. Cells in log phase were transfected in 60-mm diameter dishes with expression plasmids using Superfect transfection reagent (Qiagen, Valencia, CA) according to the manufacturer's recommendations. Cells were harvested 2 days later and lysed in ice-cold Nonidet P-40 lysis buffer (10 mM Hepes, pH 7.4, 142.5 mM KCl, 0.2% Nonidet P-40, 5 mM EGTA) supplemented with 1 mM glycerophosphate, 1 µM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, and 1 times protease inhibitor mix (Roche Molecular Biochemicals, Mannheim, Germany). Cell lysates were clarified by centrifugation at 16 000g for 5 minutes and subjected to immunoprecipitation using agarose-conjugated anti-Flag M2 antibodies (Sigma, St Louis, MO). Immunocomplexes were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. The resulting blots were incubated with anti-Myc (1:100 vol/vol, Santa Cruz Biotechnology, Santa Cruz, CA) followed by horseradish peroxidase-conjugated secondary antibodies and detection by an enhanced chemiluminescence method (ECL; Amersham Pharmacia Biotech, Buckinghamshire, United Kingdom). Alternatively, lysates were analyzed directly by immunoblotting after normalization for total protein content.Apoptosis assay The 293 cells (106) were plated per well in a 2-chamber slide and transfected by the Superfect transfection reagent (Qiagen) with various combinations of expression plasmids (total 1.3 µg) and 0.2 µg green fluorescence protein (GFP) marker plasmid pEGFP (Clontech, Palo Alto, CA). Twenty-four hours after the transfection, the percentage of GFP+ cells with nuclear apoptotic morphology was determined by fixing in 10% methanol for 15 minutes and staining with 1 µg/mL 4'-6-diamidino-2-phenylindole (DAPI) for 15 minutes (mean ± SD, n = 4).
CASP10 gene mutations Through the microdissection technique, we selectively procured tumor cells from histologic sections of 117 NHLs as shown previously.20 Genomic DNA was isolated and analyzed for potential mutations in all 10 exons in the coding region of the CASP10 gene by PCR-SSCP analysis. Enrichment and direct sequence analysis of aberrantly migrating bands led to the identification of mutations in 17 of the samples (14.5%; Table 2 and Figures 1 and 2). The mutations consisted of 14 missense, 1 nonsense, and 2 frame shift mutations (Table 2). The mutations were identified in exon 2 (n = 3), exon 7 (n = 2), exon 9 (n = 11), and exon 10 (n = 1) of the CASP10 gene. Five of the mutations in exon 9 showed an identical missense mutation. The mutation resulted in the substitution of Ala by Val at amino acid residue 414, which is next to the cleavage site between the p17 large subunit and the p12 small subunit (Table 2 and Figure 1). As for the relationship between the histologic types and the CASP10 gene mutations, the tumors with the mutations consisted of 8 diffuse large B-cell lymphomas, 1 B-cell small lymphocytic lymphoma, 2 MALT lymphomas, 2 angiocentric lymphomas, and 2 peripheral T-cell lymphomas, unclassified (Table 2). None of the corresponding normal samples showed evidence of mutations by SSCP (Figure 1), indicating the mutations detected in the NHL specimens had risen somatically. We repeated the experiments 4 times, including tissue microdissection, PCR, SSCP, and sequencing analysis to ensure the specificity of the results, and found that the data were consistent (data not shown).
Allelic status Because one of the 2 CASP10 gene mutations detected in the ALPS patients has been suggested to affect apoptosis function in a dominant-negative fashion,4 we examined the allelic status of the CASP10 gene in the tumors carrying the mutations. In addition to the previously described CASP10 gene polymorphism in exon 9,4 we also detected a novel polymorphism in exon 2 (nucleotide 177 A/G). The heterozygosity rate was 18% (18 of 100 normal healthy persons). We also analyzed the frequency of this polymorphism in the normal tissues of the NHLs. We could get normal tissues from 82 of the 117 NHLs. We found that the normal tissues from 22 cases showed this polymorphism (27%). However, the difference of these frequencies between the normal tissues of healthy population and NHLs were not statistically significant (Fisher exact test; 2-tailed, P > .05). Unfortunately, all cases with CASP10 mutations are noninformative or showed retention of heterozygosity with these 2 polymorphisms (Table 2).Instead, SSCP patterns in 2 of 17 mutations (cases 16 and 51) showed only aberrant bands of the mutant allele without those of the wild-type allele (Figure 1), and sequencing analysis also revealed only mutated sequences without wild-type ones, indicating either a homozygous mutation or a hemizygous mutation with allelic loss (Figure 1). In contrast, the other 15 cases with caspase 10 mutation showed that bands of the wild-type allele were present together with aberrant bands of the mutant allele (Figure 1). Abrogation of apoptosis activities by CASP10 mutations To determine whether the mutant forms of caspase 10 are functionally defective, we generated caspase 10 mammalian expression constructs containing the mutations found in this study by using site-directed mutagenesis. On transfection into 293 cells, we found that all mutant types showed a significant defect in apoptosis function (Figure 3B-C).
To explore how the mutants of caspase 10 impair apoptosis, we coexpressed some of the caspase 10 mutants either with Fas or TRAIL receptor 2 in 293 cells, and found that these mutants interfered with death induction by Fas or TRAIL receptor overexpression, indicating these mutants have dominant-negative inhibition of the death receptor-induced apoptosis (Figure 3D). CASP10 mutants are recruited in DISC The interference in death pathways caused by the caspase mutants (Figure 3) led us to hypothesize that the caspase mutants might be recruited into the DISC. To confirm this, we coexpressed Fas and FADD either with the Gln 257 stop mutant or the Ala414Val mutant. The coimmunoprecipitation analysis shows that FADD coimmunoprecipitates both with the Gln 257 stop mutant and FADD indicating this mutant is recruited in the DISC (Figure 4A). As a positive control, Figure 4A also shows that FADD coimmunoprecipitates both with Fas and caspase 8. In contrast, FADD did not coimmunoprecipitate with caspase 1, thus demonstrating the specificity of these results (Figure 4A). Figure 4B also shows that FADD coimmunoprecipitates both with Fas and Ala414Val mutant.
The germ line mutations of the Fas gene result in ALPS type Ia12,13 and NHL has been reported to have somatic mutations of the Fas gene.20 Inherited mutations in Fas are currently the best known genetic link between apoptosis and the regulation of lymphocyte homeostasis and immune tolerance. Moreover, caspase 10, one of the initiator caspases, is known to be essential for maintaining the equilibrium in the cells of the immune system as shown in ALPS type II.4 In addition, NHL is one of the human tumors with LOH at chromosome 2q33-34 where the CASP10 gene resides.22 Thus, we hypothesized that the neoplastic cells of NHL have the somatic mutations of the CASP10 gene and detected the somatic mutations of the CASP10 gene in 17 of 117 NHLs (14.5%). The transfection study revealed that the NHL-derived caspase 10 mutants showed a loss of apoptotic function. Also, transfection of the NHL-derived caspase 10 mutants curtailed apoptosis induction both by Fas and TRAIL receptor 2, suggesting that these caspase 10 mutants affect a signal integration point for the death receptor. Furthermore, coimmunoprecipitation revealed that the representative cases of the mutant caspase 10 are recruited into DISC together with Fas and FADD, suggesting that the DISCs formed with these mutants are not functional and block the apoptosis signaling. This is the first report on the CASP10 gene mutations in human cancers, and our data suggest that the inactivating mutations of the CASP10 gene might lead to the loss of its apoptotic signaling function and contribute to the pathogenesis of some NHLs. Caspase 10, like caspase 8, is present as an inactive proenzyme comprising a prodomain that contains 2 death effector domains (DEDs) to allow caspase 10 to interact with the DED of FADD and a catalytic protease domain that can be further processed to give a large and a small subunit.3 It has been reported that caspase 10 lacking the DEDs did not bind FADD,3 suggesting that the DED is necessary for the transduction of an apoptotic signal. Among the mutations of CASP10 found in this study, 3 mutations were identified in the coding regions of the prodomain. Interestingly, the point mutations at codons 111 and 112, which encode the region between the 2 DEDs, showed impairment of apoptosis in transfected cells (Figure 3C). These amino acid changes might lead to structural change of caspase 10 to prevent DED-DED interactions between FADD and caspase 10. A high proportion of the mutations of the CASP10 gene in the study were identified in the coding region of the p17 large subunit. The 2 inherited mutations of CASP10 gene reported in ALPS were found in the p17 large subunit and both mutants showed impaired caspase function,4 suggesting that the p17 large subunit is necessary for the enzymatic activity of caspase 10. Among the 11 tumors with the CASP10 gene mutation detected in the p17 large subunit, one nonsense mutation and 2 frame shift mutations were identified. These mutations are predicted to cause premature termination of protein synthesis, and hence resemble typical loss-of-function mutations. In case 35, C-to-T transition at bp 769 leads to a termination at codon 257, resulting in a protein that is truncated shortly after the DED-containing prodomain. This truncated mutant may be similar to FLICE-inhibitory protein (FLIP),23 which retains the ability to bind FADD but lacks the catalytic activity. Overexpression of this mutant confirmed that this mutant has a defect in induction of apoptosis (Figure 3C). We also found one mutation (case 104) in the p17 large protease domain, which is the same mutation as detected in the ALPS type II patient,4 suggesting that this mutation is functionally defective. Caspase 10 is cleaved into the p17 large protease subunit and the p12 small protease subunit at highly conserved residue (Asp 415), and this cleavage is very important for the activation of this protein.17 We identified a missense mutation that would result in an amino acid change at residue 414 just next to the cleavage site. Apoptosis by this mutant was significantly lower than that by the wild-type caspase 10 (Figure 3C), but the cleavage of the mutant caspase 10 was not different from the cleavage of wild-type caspase 10 (data not shown), indicating that apoptotic defect of this mutant dose not result from the cleavage itself. Of the 2 ALPS type II patients reported, one carried a heterozygous mutation of the CASP10 gene with dominant interference of death receptor-induced apoptosis.4 This mutant caspase 10 bound with caspase 8 and was corecruited with caspase 8 into the DISC.4 In the NHLs, 13 mutations of the CASP10 gene showed evidence of retention of the wild-type allele (Table 2). Therefore, in these cases, it is possible that the heterozygously mutated caspase 10, which inefficiently autoprocesses, and normal caspase 10 are corecruited into the DISC together with caspase 8 and could therefore block the caspase activation in a dominant-negative fashion. In contrast, the other ALPS type II patient had inherited 2 identical defective alleles from unaffected heterozygous parents in a manner of a classic mendelian recessive trait.4 The 2 CASP10 mutations in the NHL (cases 16 and 51) showed evidence of alterations of both alleles (Table 2). These biallelic inactivations of the CASP10 gene (a LOH and a mutation) may also lead to the production of mutant caspase 10 without any normal caspase 10, construct a nonfunctional DISC, and block the apoptosis signaling. Regarding 1228G>A substitution of CASP10 gene, Wang and colleagues described that none of this substitution had been found on 440 normal alleles.4 However, Grønbaek and coworkers reported that in a normal Danish population they had found the 1228G>A substitution in the heterozygous constellation (6.8%).24 In the current study, one NHL (case 106) was shown to have the 1228G>A substitution. The SSCP from the tumor DNA (case 106) showed mobility shift, whereas the SSCP from the corresponding normal DNA from the same slide section did not show any mobility shift (Figure 1A). Therefore, we concluded that the 1228G>A substitution in this study is not a polymorphism, but a mutation. There is a DED-caspase gene cluster on human chromosome 2q33-34, which contains the genes for FLIP, CASP8, and CASP10, suggesting that all of these genes have arisen by tandem duplication.17,23 Such duplications may reflect the relative instability of the chromosomal region.25 The occurrences of the CASP10 gene mutations in the NHL in the present study and the caspase 8 mutation in the head and neck cancer by another group26 indicate that CASP8 and CASP10 may be candidate tumor suppressor genes at chromosome 2q33-34. In our preliminary study, we failed to find any mutation of CASP8 gene in NHL (data not shown), suggesting that CASP10, not CASP8, may be a tumor suppressor gene in the locus. Several lines of evidence suggest that the loss of apoptosis function can enhance lymphoid tumor development. For example, lymphomatogenesis driven by the Eµ-myc transgene was shown to be markedly accelerated in lpr mice compared to wild-type mice, confirming a causal, rather than correlative, role for apoptosis loss in tumor development.27 This is well correlated with the fact that patients with ALPS type I and II have shown phenotypical abnormalities mainly in the lymphoid system.4,14,15,19,20 In this study, we have shown another suggestion, namely, that the possible apoptosis dysregulation due to the CASP10 mutation might be involved in lymphomatogenesis.
Submitted October 31, 2001; accepted January 18, 2002.
Supported by grant no. R01-1999-00093 from the Korea Science and Engineering Foundation.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Sug Hyung Lee, Department of Pathology, College of Medicine, The Catholic University of Korea, 505 Banpo-dong, Socho-gu, Seoul 137-701, Korea; e-mail: suhulee{at}cmc.cuk.ac.kr.
1. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365[CrossRef][Medline] [Order article via Infotrieve].
2.
Thompson CB.
Apoptosis in the pathogenesis and treatment of disease.
Science.
1995;267:1456-1462
3.
Vincenz C, Dixit VM.
Fas-associated death domain protein interleukin-1beta-converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death signaling.
J Biol Chem.
1997;272:6578-6583 4. Wang J, Zheng L, Lobito A, et al. Inherited human CASP10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell. 1999;98:47-58[CrossRef][Medline] [Order article via Infotrieve]. 5. Leithäser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the new growth factor/tumor necrosis receptor superfamily, in normal and neoplastic cells. Lab Invest. 1993;69:415-429[Medline] [Order article via Infotrieve].
6.
Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S.
Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responses.
Cancer Res.
1994;54:1580-1586
7.
Grønbæk K, Straten PT, Ralfkiaer E, et al.
Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity.
Blood.
1998;92:3018-3024
8.
Lee SH, Shin MS, Park WS, et al.
Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder.
Cancer Res.
1999;59:3068-3072 9. Lee SH, Shin MS, Park WS, et al. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene. 1999;18:3754-3760[CrossRef][Medline] [Order article via Infotrieve].
10.
Shin MS, Park WS, Kim SY, et al.
Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma.
Am J Pathol.
1999;154:1785-1791 11. Varfolomeev EE, Schuchmann M, Luria V, et al. Targeted disruption of the mouse CASP8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity. 1998;9:267-276[CrossRef][Medline] [Order article via Infotrieve].
12.
Rieux-Laucat F, Le Deist F, Hivroz C, et al.
Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.
Science.
1995;268:1347-1349 13. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest. 1996;98:1107-1113[Medline] [Order article via Infotrieve].
14.
Dianzani U, Bragardo M, DiFranco D, et al.
Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation.
Blood.
1997;89:2871-2879
15.
Sneller MC, Wang J, Dale JK, et al.
Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
Blood.
1997;89:1341-1348
16.
Yeh WC, Pompa JL, McCurrach ME, et al.
FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis.
Science.
1998;279:1954-1958
17.
Fernandes-Alnemri T, Armstrong RC, Krebs J, et al.
In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains.
Proc Natl Acad Sci U S A.
1996;93:7464-7469 18. Mitelman F, Mertens F, Johansson B. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet. 1997;15:417-474[CrossRef][Medline] [Order article via Infotrieve].
19.
Harris NL, Jaffe ES, Stein H, et al.
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
Blood.
1994;84:1361-1392 20. Lee JY, Dong SM, Kim SY, Yoo NJ, Lee SH, Park WS. A simple, precise and economical microdissection technique for analysis of genomic DNA from archival tissue sections. Virchows Arch. 1998;433:305-309[CrossRef][Medline] [Order article via Infotrieve].
21.
Ng PW, Porter AG, Janicke RU.
Molecular cloning and characterization of two novel pro-apoptotic isoforms of caspase-10.
J Biol Chem.
1999;274:10301-10308 22. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356:314-317[CrossRef][Medline] [Order article via Infotrieve]. 23. Grenet J, Teitz T, Wei T, Valentine V, Kidd VJ. Structure and chromosome localization of the human CASP8 gene. Gene. 1999;226:225-232[CrossRef][Medline] [Order article via Infotrieve].
24.
Grønbæk K, Darby T, Zeuthen J, Ralfkaiser E, Guidberg P.
The V410I (G1228A) variant of the caspase-10 gene is a common polymorphism of the Danish population.
Blood.
2000;95:2184-2185 25. Baens M, Aerssens J, van Zand K, Van den Berghe H, Marynen P. Isolation and regional assignment of human chromosome 12p cDNAs. Genomics. 1995;29:44-52[CrossRef][Medline] [Order article via Infotrieve].
26.
Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen PA.
CASP-8 mutation recognized by cytotoxic T lymphocytes on a human head and neck carcinoma.
J Exp Med.
1997;186:785-793 27. Zörnig M, Grzeschiczek A, Kowalski MB, Hartmann KU, Möröy T. Loss of Fas/APO-1 receptor accelerates lymphomagenesis in Eµ L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene. 1995;10:2397-2401[Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S Ghavami, M Hashemi, S R Ande, B Yeganeh, W Xiao, M Eshraghi, C J Bus, K Kadkhoda, E Wiechec, A J Halayko, et al. Apoptosis and cancer: mutations within caspase genes J. Med. Genet., August 1, 2009; 46(8): 497 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Lan, L. M. Morton, B. Armstrong, P. Hartge, I. Menashe, T. Zheng, M. P. Purdue, J. R. Cerhan, Y. Zhang, A. Grulich, et al. Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studies Blood, July 9, 2009; 114(2): 264 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mestdagh, T. Feys, N. Bernard, S. Guenther, C. Chen, F. Speleman, and J. Vandesompele High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA Nucleic Acids Res., December 1, 2008; 36(21): e143 - e143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Lan, T. Zheng, S. Chanock, Y. Zhang, M. Shen, S. S. Wang, S. I. Berndt, S. H. Zahm, T. R. Holford, B. Leaderer, et al. Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma Carcinogenesis, April 1, 2007; 28(4): 823 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Kim, I. Chang, J. Y. Kim, K.-H. Choi, and M.-S. Lee Caspase-Mediated p65 Cleavage Promotes TRAIL-Induced Apoptosis Cancer Res., July 15, 2005; 65(14): 6111 - 6119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. H. Engels, G. Totzke, U. Fischer, K. Schulze-Osthoff, and R. U. Janicke Caspase-10 Sensitizes Breast Carcinoma Cells to TRAIL-Induced but Not Tumor Necrosis Factor-Induced Apoptosis in a Caspase- 3-Dependent Manner Mol. Cell. Biol., April 1, 2005; 25(7): 2808 - 2818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Reis, E. P.B. Ojopi, F. L. Alberto, P. Rahal, F. Tsukumo, U. M. Mancini, G. S. Guimaraes, G. M.A. Thompson, C. Camacho, E. Miracca, et al. Large-scale Transcriptome Analyses Reveal New Genetic Marker Candidates of Head, Neck, and Thyroid Cancer Cancer Res., March 1, 2005; 65(5): 1693 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. H. Soung, J. W. Lee, S. Y. Kim, J. Jang, Y. G. Park, W. S. Park, S. W. Nam, J. Y. Lee, N. J. Yoo, and S. H. Lee CASPASE-8 Gene Is Inactivated by Somatic Mutations in Gastric Carcinomas Cancer Res., February 1, 2005; 65(3): 815 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. MacPherson, C. S. Healey, M. D. Teare, S. P. Balasubramanian, M. W. R. Reed, P. D. P. Pharoah, B. A. J. Ponder, M. Meuth, N. P. Bhattacharyya, and A. Cox Association of a Common Variant of the CASP8 Gene With Reduced Risk of Breast Cancer J Natl Cancer Inst, December 15, 2004; 96(24): 1866 - 1869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Lee, Y. H. Soung, S. Y. Kim, S. W. Nam, C. J. Kim, Y. G. Cho, J. H. Lee, H. S. Kim, W. S. Park, S. H. Kim, et al. Inactivating mutations of proapoptotic Bad gene in human colon cancers Carcinogenesis, August 1, 2004; 25(8): 1371 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Sriuranpong, A. Mutirangura, J. W. Gillespie, V. Patel, P. Amornphimoltham, A. A. Molinolo, V. Kerekhanjanarong, S. Supanakorn, P. Supiyaphun, S. Rangdaeng, et al. Global Gene Expression Profile of Nasopharyngeal Carcinoma by Laser Capture Microdissection and Complementary DNA Microarrays Clin. Cancer Res., August 1, 2004; 10(15): 4944 - 4958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Fortugno, E. Beltrami, J. Plescia, J. Fontana, D. Pradhan, P. C. Marchisio, W. C. Sessa, and D. C. Altieri Regulation of survivin function by Hsp90 PNAS, November 25, 2003; 100(24): 13791 - 13796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. P. Blanc-Brude, M. Mesri, N. R. Wall, J. Plescia, T. Dohi, and D. C. Altieri Therapeutic Targeting of the Survivin Pathway in Cancer: Initiation of Mitochondrial Apoptosis and Suppression of Tumor-associated Angiogenesis Clin. Cancer Res., July 1, 2003; 9(7): 2683 - 2692. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
